Immunity to Immunotherapy in Cancer

Experienced Associate Professor in Pharmacology with a demonstrated history of working in national and international organisations. Strong professional skilled in Pharmaceutical Research, Molecular Biology, Inflammation, and cardiovascular and metabolic diseases. Dr. Deepa Mandlik is an Associate Professor at Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune. She brings extensive teaching and research experience across her career and has demonstrated outstanding academic achievement in her early training. She has published extensively in reputable national and international journals and has authored several pharmaceutical books along with multiple international book chapters. A recognized PhD guide, she mentors doctoral researchers and oversees a active cohort of postgraduate students. She is a life member of APTI and a member of CRS-Indian Chapter. Her research interests encompass nanotechnology, targeted drug delivery, quality by design, design of experiments, and optimization techniques, reflecting a strong commitment to innovation in pharmaceutical science. Dr. Mandlik is known for integrating rigorous scientific inquiry with teaching and mentorship to advance the development of the next generation of pharmaceutical researchers.

• Part A: Cancer Immunity1. Introduction to Immunity in Cancer2. Role of Innate Immunity in Cancer Immunology3. Role of Dendritic Cells in Cancer Immunology4. Role of Natural Killer Cells in Cancer Immunology5. Role of B-Cells in Tumor Immunity6. Role of CD4+ T-Cells in Cancer Immunology7. Role of Regulatory T-Cells and Th17 Cells in Tumor Microenvironment8. Role of Monocytes, Macrophages, and Polymorphonuclear Cells in Cancer Immunology9. Role of Cytokines in Cancer Immunology10. Role of Chemokines and Chemokine Receptors in Cancer Immunology11. Role of the Inflammasome in Cancer Immunology12. Current Advanced Immunological Tools and Databases in Tumor Immunity13. Tumor Heterogeneity and Therapeutic ResistancePart B: Cancer Immunotherapy14. Cancer Immunotherapy: Pros, Cons, and Beyond15. Role of Monoclonal Antibody, Immune Checkpoint Inhibitors, and Programmed Death Ligand 1 in Cancer Immunotherapy16. Role of Chimeric Antigen Receptor-T Cell in Cancer Immunotherapy17. Role of Small Molecule-Based Drugs in Cancer Immunotherapy18. Role of Adoptive Cell Therapy in Cancer Immunotherapy19. Role of Cancer Vaccines in Cancer Immunotherapy20. Role of Radiotherapy/Chemotherapy in Cancer Immunotherapy